Skip to content
Open access

Does etiology matter only in HFmrEF? Data from the HEart failuRe ObsErvational Study (HEROES)

Oct 2026 · Archives of Medical Science · 0 citations · 29 references

TL;DR

The prognostic impact of HF etiology appears phenotype-dependent, concentrated within HFmrEF, where non-ischemic etiology substantially worse survival, and warrants confirmation.

Abstract

Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) is a heterogeneous phenotype, and whether the prognostic weight of ischemic versus non-ischemic etiology differs across left ventricular ejection fraction (LVEF) categories remains uncertain. We examined whether the association between etiology and long-term all-cause mortality is modified by HF phenotype. Within the prospective multicenter HEROES registry, 1,410 patients with HF were classified as having ischemic or non-ischemic etiology and categorized by LVEF. All-cause mortality was obtained through national administrative linkage with complete follow-up. Entropy balancing (13 covariates) and weighted Cox models were applied within each phenotype, with formal testing for etiology-by-phenotype interaction. Robustness was evaluated using restricted mean survival time (RMST), the E-value, and sensitivity analyses. Over a median follow-up of 14.8 months, 219 (15.5%) deaths occurred. Crude mortality was identical between etiologies (15.5% vs. 15.5%; p = 0.93). After balancing, no difference was observed in HFrEF (adjusted hazard ratio [aHR] 1.03, 95% CI: 0.68–1.58) or HFpEF (aHR = 0.84, 95% CI: 0.37–1.90), whereas non-ischemic etiology was associated with higher mortality in HFmrEF (aHR = 3.99, 95% CI: 1.51–10.51; p = 0.005). The etiology-by-phenotype interaction was significant (p = 0.032). In HFmrEF, the RMST difference at 23 months was −2.38 months (95% CI: −3.69 to −1.00), with an E-value of 4.55 (lower confidence limit 1.99); findings were consistent across sensitivity analyses. The prognostic impact of HF etiology appears phenotype-dependent, concentrated within HFmrEF, where non-ischemic etiology substantially worse survival. Given the limited number of events, this phenotype-specific signal is hypothesis-generating and warrants confirmation.

Read PDF

Similar papers

Oct 2026

History of hypertension is associated with improved survival in patients with nonischemic etiology of heart failure and reduced ejection fraction.

BACKGROUND Hypertension (HTN) is a common comorbidity in patients with heart failure with reduced ejection fraction (HFrEF), yet its prognostic significance remains complex. OBJECTIVE To evaluate the association between HTN and all-cause mortality in patients with HFrEF, stratified by ischemic and nonischemic etiolog...

Daniel Zango, V. Copeland, Y. Wasserstrum et al. · 0 citations
Open access Oct 2026

Cause and circumstances of death in contemporary heart failure: nationwide analysis across EF and etiological subtypes

Heart failure (HF) remains associated with high mortality despite therapeutic advances. In elderly patients, the cause, mode and location of death may be as clinically relevant as survival itself. However, contemporary population-level data across ejection fraction (EF) and etiological subtypes are limited....

A. Lyon, M. Lindgren, K. Konstantinou et al. · 0 citations
Open access Oct 2026

Beyond Cardiorenal Risk Factors: The Prognostic Role of Frailty in Acute Heart Failure

Background: Frailty is highly prevalent in acute heart failure (AHF), yet whether it is more strongly associated with all-cause mortality or with non-fatal heart-failure events, and whether it adds information beyond cardiac severity, is seldom examined. Methods: In a prospective single-center registry of 530 consecuti...

G. Aletras, M. Marketou, M. Bachlitzanaki et al. · 0 citations
Oct 2026

Beyond LVEF: morbidity burden (GMA) as the main predictor of mortality and outcomes in heart failure

In this large population-based cohort of patients with heart failure, the Adjusted Morbidity Group (GMA) emerged as the strongest independent predictor of all-cause mortality, reamission for heart failure and healthcare costs in the multivariable model.

H. T. Marcos, E. Vela, R. Casanovas et al. · 0 citations
Oct 2026

Sex Differences in the Prevalence, Medical Therapy, and Outcomes in Heart Failure With Improved Ejection Fraction.

BACKGROUND Heart failure with improved ejection fraction (HFimpEF) is a rapidly growing clinical entity. There is little understanding of how sex relates to the epidemiology, predictors, and trajectory of HFimpEF. OBJECTIVES The authors aimed to describe sex-based differences in the epidemiology, guideline-directed m...

Yi-Lin Liang, Lochan M. Shah, R. Parikh et al. · 1 citation
Oct 2026

Unrecognized heart failure with preserved ejection fraction in COPD: phenotyp-ing a prospective cohort using the HFA-PEFF score

In a COPD population without known heart failure, higher HFpEF probability was common and associated with cardiopulmonary risk factors, impaired cardiac function, and worse clinical outcomes, according to the HFA-PEFF score.

L. S. Duus, D. Vesterlev, E. H. Janner et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.